Bay Colony Advisory Group Inc d b a Bay Colony Advisors Acquires 834 Shares of Johnson & Johnson (JNJ)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 15.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,390 shares of the company’s stock after acquiring an additional 834 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Johnson & Johnson were worth $825,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in JNJ. Evolution Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $40,000. Horan Securities Inc. increased its holdings in shares of Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares during the last quarter. Stuart Chaussee & Associates Inc. increased its holdings in shares of Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 80 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in shares of Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after buying an additional 428 shares during the last quarter. Finally, CKW Financial Group increased its holdings in shares of Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after buying an additional 128 shares during the last quarter. Institutional investors own 66.91% of the company’s stock.

Shares of NYSE:JNJ opened at $138.12 on Wednesday. The firm has a market capitalization of $371.88 billion, a PE ratio of 16.89, a P/E/G ratio of 2.40 and a beta of 0.67. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.13 and a current ratio of 1.44.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The company had revenue of $20.02 billion for the quarter, compared to analyst estimates of $19.55 billion. During the same quarter last year, the firm earned $2.06 EPS. The firm’s quarterly revenue was up .1% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Friday, May 24th. This represents a $3.80 annualized dividend and a dividend yield of 2.75%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is currently 44.01%.

JNJ has been the topic of a number of research analyst reports. Barclays reissued an “equal weight” rating and issued a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $151.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Wells Fargo & Co reissued an “outperform” rating and issued a $157.00 price target (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Citigroup increased their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a report on Monday, February 25th. Finally, Raymond James increased their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $147.30.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/22/bay-colony-advisory-group-inc-d-b-a-bay-colony-advisors-acquires-834-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is a recession?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.